We are live on ! Find out more
CPXX

CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX

Delisted

CPXX was delisted on the 11th of July, 2016.

Back to rankings

0 hedge funds and large institutions have $0 invested in CELATOR PHARMACEUTICALS INC. COMMON STOCK in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 117 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 119 → 0 (-119)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $944M → $0 (-$944M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 117

Holders
–
Holders Change
-119
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
117
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
-$67.4M
2
AAM
Alpine Associates Management
Florida
-$66.9M
3
MF
Magnetar Financial
Illinois
-$48M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$37.9M
5
ACA
Avoro Capital Advisors
New York
-$33.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAC
26
OMERS Administration Corp
Ontario, Canada
– -$13.1M -433,500 Closed
COPPSERS
27
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$12.5M -413,223 Closed
Northern Trust
28
Northern Trust
Illinois
– -$10.6M -350,881 Closed
UOC
29
UBS O'Connor
Illinois
– -$10.1M -336,115 Closed
DKCM
30
Davidson Kempner Capital Management
New York
– -$9.81M -325,000 Closed
SCM
31
Stevens Capital Management
Pennsylvania
– -$9.77M -323,766 Closed
Goldman Sachs
32
Goldman Sachs
New York
– -$9.77M -323,663 Closed
PCM
33
Pentwater Capital Management
Florida
– -$9.52M -315,400 Closed
LIM
34
Longfellow Investment Management
Massachusetts
– -$8.75M -290,000 Closed
GI
35
GAMCO Investors
Connecticut
– -$8.28M -274,202 Closed
KPF
36
K2 Principal Fund
Ontario, Canada
– -$8.13M -269,547 Closed
FNYS
37
First New York Securities
New York
– -$7.63M -252,691 Closed
OP
38
Omni Partners
United Kingdom
– -$7.06M -233,924 Closed
Geode Capital Management
39
Geode Capital Management
Massachusetts
– -$6.83M -226,185 Closed
Marshall Wace
40
Marshall Wace
United Kingdom
– -$4.94M -163,590 Closed
GP
41
GLG Partners
United Kingdom
– -$4.8M -159,041 Closed
PCM
42
Prelude Capital Management
New York
– -$4.75M -157,338 Closed
Barclays
43
Barclays
United Kingdom
– -$4.61M -152,849 Closed
HM
44
Harvest Management
New York
– -$4.53M -150,000 Closed
Bank of New York Mellon
45
Bank of New York Mellon
New York
– -$4.22M -139,790 Closed
D.E. Shaw & Co
46
D.E. Shaw & Co
New York
– -$4.01M -132,752 Closed
BIM
47
BlackRock Investment Management
Delaware
– -$3.84M -127,214 Closed
LP
48
LMR Partners
United Kingdom
– -$3.77M -125,000 Closed
WAM
49
Wolverine Asset Management
Illinois
– -$3.25M -107,748 Closed
SMC
50
S. Muoio & Co
New York
– -$3.16M -104,600 Closed
1
2
3 4 5

CPXX Hedge Fund Activity: Q3 2016 in Review

0 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) for Q3 2016, worth a combined $0 — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 117 funds closed out of CPXX and 0 opened new positions — a net loss of 117 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Caxton Corporation, exiting entirely with an estimated $67.4M sold.

  • 0 institutional investors held CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) as of Q3 2016, down from 119 in Q2 2016.
  • Funds reported $0 of CELATOR PHARMACEUTICALS INC. COMMON STOCK stock for Q3 2016, down 100% quarter-over-quarter.
  • 0 funds opened new CELATOR PHARMACEUTICALS INC. COMMON STOCK positions in Q3 2016 and 117 closed out, a net change of -117 holders.
  • The largest CELATOR PHARMACEUTICALS INC. COMMON STOCK seller in Q3 2016 was Caxton Corporation, an estimated $67.4M sold.

Based on aggregated 13F filings for Q3 2016.